Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
Gilead Sciences: Revised Revenue Projections To 2030 - This Momentum Stock Is Still A Buy
03:44pm, Tuesday, 10'th Jan 2023
Gilead is the stock with most momentum in a sector - big pharma - that performed exceptionally well in 2022. The company is already an HIV giant but CEO Daniel O'Day has been given the task of creatin
Dividend Income Update: December 2022
12:30am, Tuesday, 10'th Jan 2023
Dividend investing can work over time and anyone can create an ever growing passive income stream. My year over year progress is moving at a nice clip.
Gilead Sciences, Inc. (GILD) J.P. Morgan Annual Healthcare Conference (Transcript)
04:15pm, Monday, 09'th Jan 2023
Gilead Sciences, Inc. (NASDAQ:GILD ) J.P. Morgan Annual Healthcare Conference January 9, 2023 1:30 PM ET Company Participants Daniel O'Day - Chairman and CEO Johanna Mercier - Chief Commercial Officer
Gilead CEO Daniel O'Day: Ending the HIV epidemic is our goal
08:35am, Monday, 09'th Jan 2023
Gilead CEO Daniel O'Day joins 'Squawk Box' to discuss his outlook for the biopharma industry and more.
Better Large-Cap Buy: Roche Holding or Gilead Sciences Stock?
09:00am, Monday, 02'nd Jan 2023
Which of these companies is better able to replace declining COVID-19-related sales?
100 Best Stocks Of 2022: Oil Stocks And Medicals Shine
06:00pm, Friday, 30'th Dec 2022
Medical and energy companies, including oil stocks, lead the list of the 100 best stocks in 2022. The post 100 Best Stocks Of 2022: Oil Stocks And Medicals Shine appeared first on Investor's Business
This New Drug Could Be Gilead Sciences' Growth Catalyst
09:20am, Thursday, 29'th Dec 2022
Another potential blockbuster drug in Gilead's hands.
Biotech: 3 Profitable Bios Worth Owning
03:22pm, Wednesday, 28'th Dec 2022
The biotechnology space can be a difficult area to generate profits. Drugs take years to develop and often fail FDA approval.
Gilead (GILD) To Get Full Rights for Jounce's Immunotherapy
12:21pm, Wednesday, 28'th Dec 2022
Gilead Sciences (GILD) is set to buy the remaining rights to the potential first-in-class immunotherapy GS-181 from Jounce Therapeutics.
Gilead buys out rights to cancer therapy from Jounce for $67 mln
09:34pm, Tuesday, 27'th Dec 2022
Gilead Sciences will buy all the remaining rights for an experimental cancer therapy, GS-1811, from Jounce Therapeutics for $67 million, the drugmaker said on Tuesday.
Jounce stock bounces more than 70% after Gilead acquires immunotherapy drug
04:49pm, Tuesday, 27'th Dec 2022
Jounce Therapeutics Inc. JNCE, -6.66% shares jumped more than 70% in after-hours trading Tuesday, following an announcement that Gilead Sciences Inc. GILD, +0.31% would completely acquire rights to an
4 Top Biotech Stocks Worth Adding to Your Portfolio in 2023
12:47pm, Tuesday, 27'th Dec 2022
New drug approvals and focus on coronavirus treatments should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, GSK, IMCR
3 Stocks That Could Soar in a Santa Claus Rally
07:45am, Sunday, 25'th Dec 2022
These stocks are primed for a holiday surge.
Gilead Sciences to Present at Upcoming Investor Conference
04:05pm, Friday, 23'rd Dec 2022
FOSTER CITY, Calif.--( BUSINESS WIRE )--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference:
Gilead (GILD) Gets FDA Nod for Twice-Yearly HIV Treatment
01:32pm, Friday, 23'rd Dec 2022
Gilead'ls (GILD) HIV franchise gets a boost with FDA's approval of twice-yearly HIV treatment Sunlenca for the treatment of HIV-1 infection in heavily treatment-experienced adults with multi-drug resi
